Latest filing published 27 Feb 2024 for T2 Biosystems, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -13.4%Entry US$48.50 · Close at T+365 US$42.00
- +177.4%Entry US$336.00 · Close at T+365 US$932.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael Terrence Gibbs: trading record in brief
Michael Terrence Gibbs (senior executive) discloses dealings in T2 Biosystems, Inc. to SEC (Form 4). Over a trading history stretching from 6 June 2017 to 24 February 2024, the count stands at 41 filings.
The open-market side counts 2 purchases for €4,513 alongside 12 sales for €60k. Sales outweigh purchases by €56k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 8 share grants and 19 option exercises.
The newest entry dates from 27 February 2024: an option exercise, in T2 Biosystems, Inc. The last insider purchase was made public on 11 April 2022, 1,672 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Michael Terrence Gibbs
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 29 sharesCommon StockSEC:0000950170-24-021242:0
- 40 sharesCommon StockSEC:0000950170-24-017073:0
- 239 shares@ US$0.4812.3% of flowCommon StockSEC:0000950170-23-012031:0
- 334 sharesCommon StockSEC:0000899243-23-010680:0
- 333 sharesCommon StockSEC:0000950170-23-010276:0
- 2,145 shares@ US$0.650.0% of flowCommon StockSEC:0000899243-23-007725:1
- 1,585 shares@ US$0.590.0% of flowCommon StockSEC:0000899243-23-007725:3
- 2,914 sharesCommon StockSEC:0000899243-23-007725:2
- 4,000 sharesCommon StockSEC:0000899243-23-007725:0
- 10,000 shares@ US$0.4997.7% of flowCommon StockSEC:0000899243-22-014416:0Canonical exit: 6 Jul 2022 (T+90)
- 8,790 shares@ US$0.4409Common StockSEC:0000899243-22-012515:1
- 16,666 sharesCommon StockSEC:0000899243-22-012515:0
- 145,719 sharesCommon StockSEC:0000899243-22-012514:0
- 10,000 sharesCommon StockSEC:0000899243-22-012511:0
- 76,867 shares@ US$0.4488Common StockSEC:0000899243-22-008055:1
- 145,719 sharesCommon StockSEC:0000899243-22-008055:0
- 5,275 shares@ US$0.466Common StockSEC:0000899243-22-007489:1
- 10,000 sharesCommon StockSEC:0000899243-22-007489:0
- 8,758 shares@ US$1.560.0% of flowCommon StockSEC:0000899243-21-013462:1
- 16,667 sharesCommon StockSEC:0000899243-21-013462:0
- 7,280 shares@ US$2.060.0% of flowCommon StockSEC:0000899243-21-007776:1
- 10,000 sharesCommon StockSEC:0000899243-21-007776:0
- 10,000 sharesCommon StockSEC:0000899243-20-005806:0
- 5,808 shares@ US$0.820.0% of flowCommon StockSEC:0000899243-20-005806:1
- 5,833 sharesCommon StockSEC:0000899243-20-004327:0
25 of 39 declarations